302 PLX4720 and Preclinical Thyroid Cancer Models Figure 3. Migration and invasion assays with PLX4720 treatment in thyroid cancer cell models. Treatment with 1 M (A) or 10 M (B) PLX4720 reduced migration and invasion in 8505c cells (***p .001). (B): Migration of TPC-1 cells was lower with 10 M PLX4720 (***p .001). (C): PLX4720 inhibited p-ERK-1/ERK-2 in B-RafV600E-overexpressed primary human NT follic- ular cells, compared with NT cells transduced with the EV. (D): Migration and invasion of NT cells with B-RafV600E overexpres- sion were inhibited by PLX4720 (***p .001). Abbreviations: ERK, extracellular signal–related kinase; EV, empty vector; NT, normal thyroid; p, phosphorylated; wt, wild-type. mg/kg per day for 21 days) by oral gavage and eight re- ceived control gavage. Control mice began to lose weight and develop dramatic signs of cachexia at approximately 28 days. By 35 days, all controls showed evidence of cachexia